On November 15, 2025, ActiMaris® showed its strongest side at the renowned APTFeridas Congress in Portugal. Under the title “ActiMaris – do esquisso à obra-prima“, experienced clinicians presented impressive case studies that impressively demonstrated what modern wound care looks like today – safe, effective and measurably successful.
The symposium was made possible by our valued partner EUROPHARMA, which is firmly anchoring ActiMaris® in everyday clinical practice in Portugal.
Clinical highlights from the ActiMaris Symposium
1. cardiosurgery: from dehiscence to safe healing
Filipe Gomes presented a challenging case from cardiac surgery wound care. His contribution showed how ActiMaris® contributes to stabilization, cleansing and rapid reduction of inflammation – a decisive advantage in post-operative dehiscences where every hour counts.
2. leg ulcer: (Re)Tratar com ActiMaris®
Ana Amorim & Olívia Rodrigues showed how chronic ulcers were successfully reassessed and treated with ActiMaris® in a private hospital. Particularly highlighted were:
- Significant reduction in fibrinous deposits
- Control of biofilm and bacterial load
- Visible acceleration of granulation
3. complex wounds: Safety meets efficacy
Alexandra Loureiro & Cristina Silva presented a series of complex cases in which ActiMaris® proved to be a reliable partner in daily practice. The combined physico-chemical action of the ActiMaris complex – hypertonic, alkaline, rich in singular oxygen – was emphasized as the central key to improving the wound environment.
Why ActiMaris® was so present at this congress
The APTFeridas congress is one of the most important Portuguese specialist events for wound management. The fact that ActiMaris® was represented with its own symposium is proof of this:
- the increasing clinical acceptance in Portugal
- the strong partnership with EUROPHARMA
- the growing scientific interest in the ActiMaris complex
- the need for modern solutions for complex and infected wounds
ActiMaris® is increasingly seen as a “simple medical solution designed by nature” – a technology that combines safety, biocompatibility and clinical efficacy.
A strong conclusion
The case studies presented have clearly shown one thing:
ActiMaris® supports clinicians where conventional products reach their limits – in the treatment of complex, infected and stagnant wounds.
We would like to thank Filipe Gomes, Ana Amorim, Olívia Rodrigues, Alexandra Loureiro and Cristina Silva as well as our partner EUROPHARMA for their outstanding cooperation.
